Three retrospective studies have compared erlotinib with gefitinib beyond first‐line therapy in NSCLC patients, all of which reported similar efficacy and outcomes between erlotinib and gefitinib, regardless of EGFR status 24, 25, 26. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.